Low-dose colchicine for atherosclerotic cardiovascular disease and the return of inflammation-targeted pharmacotherapy.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert opinion synthesizing published trials without new empirical data or systematic review methodology.
PubMed 42453064 · doi:10.1080/14656566.2026.2705345
What was done
This narrative review synthesized evidence on low-dose colchicine (0.5 mg) as an oral anti-inflammatory therapy for atherosclerotic cardiovascular disease (ASCVD). It evaluated pivotal randomized trial evidence (including COLCOT, LoDoCo2, and CLEAR SYNERGY/OASIS-9), safety profiles, drug-drug interactions, regulatory approval, and proposed an integrated clinical framework for patient selection across acute and chronic coronary settings.
What was found
The abstract reports no quantitative outcome numbers or effect estimates. It qualitatively summarizes positive secondary prevention data from COLCOT (post-myocardial infarction) and LoDoCo2 (chronic coronary disease) leading to FDA approval, contrasted with neutral outcomes reported from the CLEAR SYNERGY/OASIS-9 trial in acute myocardial infarction.
Why it matters
Colchicine offers an oral, cost-effective option to address residual inflammatory risk in ASCVD. This review provides clinicians with a structured decision framework accounting for ischemic risk, inflammatory phenotype, tolerability, and renal, hepatic, or drug interaction risks.
Limits
As a narrative review, it contains no new empirical patient data or systematic meta-analytic pooling. The abstract lacks quantitative efficacy and safety statistics and highlights lingering uncertainty regarding efficacy in the acute post-myocardial infarction setting.
Cited by
- supports A specific dose of colchicine significantly reduces cardiovascular risk in patients with a prior heart attack, particularly those with diabetes, and is FDA approved for this indication.